Stephens Sticks to Their Buy Rating for Option Care Health (OPCH)
Stephens analyst Kyle Evans maintained a Buy rating on Option Care Health today and set a price target of $40.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Evans is ranked #1968 out of 12078 analysts.
In addition to Stephens, Option Care Health also received a Buy from Morgan Stanley’s Erin Wright in a report issued today. However, on the same day, TipRanks – Google downgraded Option Care Health (NASDAQ: OPCH) to a Hold.
Based on Option Care Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.47 billion and a net profit of $58.5 million. In comparison, last year the company earned a revenue of $1.35 billion and had a net profit of $60.13 million
Read More on OPCH:
Disclaimer & DisclosureReport an Issue
- Buy Rating Maintained as Stelara Headwind Fades and Core Profitability Remains Stable
- Option Care Health reports Q4 adjusted EPS 46c, consensus 47c
- Option Care Health sees FY26 adjusted EPS $1.82-$1.92, consensus $1.87
- OPCH Upcoming Earnings Report: What to Expect?
- Option Care Health price target raised to $37 from $27 at TD Cowen
